Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
HOUSTON, March 06, 2017 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Monday, March 13, 2017 at 5:00 p.m. Eastern to report its fourth quarter and full year 2016 financial results and provide a corporate update.
To access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investor and Media section of the Bellicum website for at least two weeks following the call.
About Bellicum Pharmaceuticals
Bellicum is a leader in developing novel, controllable cellular immunotherapies for cancers and for orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors: Bellicum Pharmaceuticals, Inc. Alan Musso, CFO 832-384-1116 [email protected] Media: BMC Communications Brad Miles, 646-513-3125 [email protected]
